13.57
Schlusskurs vom Vortag:
$13.34
Offen:
$13.26
24-Stunden-Volumen:
1.71M
Relative Volume:
0.49
Marktkapitalisierung:
$1.55B
Einnahmen:
$631.73M
Nettoeinkommen (Verlust:
$-239.78M
KGV:
-6.7178
EPS:
-2.02
Netto-Cashflow:
$-33.45M
1W Leistung:
-4.97%
1M Leistung:
-0.80%
6M Leistung:
+28.99%
1J Leistung:
-40.66%
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Vergleichen Sie TXG mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
TXG
10 X Genomics Inc
|
13.57 | 1.66B | 631.73M | -239.78M | -33.45M | -2.02 |
![]()
VEEV
Veeva Systems Inc
|
270.06 | 44.25B | 2.97B | 809.93M | 1.33B | 4.87 |
![]()
TEM
Tempus Ai Inc
|
78.12 | 13.61B | 803.32M | -709.10M | -212.68M | -7.8003 |
![]()
DOCS
Doximity Inc
|
68.52 | 12.55B | 550.17M | 201.35M | 232.07M | 1.00 |
![]()
HQY
Healthequity Inc
|
97.70 | 7.68B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
WAY
Waystar Holding Corp
|
37.23 | 6.45B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
2024-06-03 | Fortgesetzt | Jefferies | Hold |
2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
2023-12-14 | Eingeleitet | Guggenheim | Buy |
2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
2023-05-10 | Eingeleitet | Barclays | Overweight |
2023-03-31 | Eingeleitet | Stephens | Overweight |
2023-02-02 | Eingeleitet | UBS | Neutral |
2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
2021-10-15 | Fortgesetzt | Cowen | Outperform |
2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
2021-03-15 | Eingeleitet | William Blair | Outperform |
2020-12-02 | Eingeleitet | Goldman | Neutral |
2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
2020-07-10 | Eingeleitet | Stifel | Buy |
2020-03-05 | Eingeleitet | Guggenheim | Buy |
2020-01-07 | Eingeleitet | Citigroup | Buy |
2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
2019-10-07 | Eingeleitet | Cowen | Outperform |
2019-10-07 | Eingeleitet | JP Morgan | Overweight |
2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
Is 10x Genomics Inc. a potential multi baggerPortfolio Return Report & Real-Time Volume Trigger Notifications - khodrobank.com
Is this a good reentry point in 10x Genomics Inc.Quarterly Performance Summary & Target Return Focused Stock Picks - Newser
Is 10x Genomics Inc. still worth holding after the dip2025 Year in Review & Free Community Consensus Stock Picks - Newser
Does 10x Genomics Inc. meet Warren Buffett’s criteriaTrade Signal Summary & Short-Term High Return Ideas - khodrobank.com
Detecting price anomalies in 10x Genomics Inc. with AIJuly 2025 PostEarnings & Weekly Chart Analysis and Guides - Newser
Technical analysis overview for 10x Genomics Inc. stockJuly 2025 Sector Moves & Verified Short-Term Plans - Newser
Chart based analysis of 10x Genomics Inc. trends2025 Retail Activity & Safe Entry Zone Identification - Newser
Applying big data sentiment scoring on 10x Genomics Inc.July 2025 Analyst Calls & Growth Focused Investment Plans - Newser
What the charts say about 10x Genomics Inc. todayJuly 2025 Patterns & Verified Technical Signals - Newser
Should you wait for a breakout in 10x Genomics Inc.Stop Loss & AI Driven Price Forecasts - Newser
Multi asset correlation models including 10x Genomics Inc.Market Growth Review & Low Drawdown Investment Ideas - Newser
Will earnings trigger a reversal in 10x Genomics Inc.July 2025 Recap & Expert Approved Momentum Trade Ideas - Newser
Using economic indicators to assess 10x Genomics Inc. potentialJuly 2025 Selloffs & Weekly Momentum Picks - Newser
10x Genomics Investment Opportunity: Sell Puts for 20.3% Annualized Return - AInvest
Commit To Buy 10x Genomics At $10, Earn 20.3% Annualized Using Options - Nasdaq
Can 10x Genomics Inc. sustain earnings growthCPI Data & Weekly Top Gainers Trade List - khodrobank.com
What MACD signals say about 10x Genomics Inc.July 2025 Opening Moves & AI Based Buy/Sell Signal Reports - Newser
Visual analytics tools that track 10x Genomics Inc. performanceWeekly Market Outlook & Low Volatility Stock Suggestions - Newser
10x Genomics, Inc. (TXG) Stock Analysis: Assessing the 7.62% Potential Upside for Investors - DirectorsTalk Interviews
Is 10x Genomics Inc. stock a good pick for beginnersPortfolio Profit Report & Daily Entry Point Trade Alerts - khodrobank.com
Volume spikes in 10x Genomics Inc. stock – what they meanJuly 2025 Update & Short-Term Trading Opportunity Alerts - Newser
Trend analysis for 10x Genomics Inc. this weekJuly 2025 Snapshot & Safe Capital Allocation Plans - Newser
Analyzing drawdowns of 10x Genomics Inc. with statistical toolsJuly 2025 Final Week & Capital Protection Trading Alerts - Newser
What earnings revisions data tells us about 10x Genomics Inc.July 2025 Closing Moves & Weekly Setup with ROI Potential - Newser
Is 10x Genomics Inc. stock a buy or sellWeekly Risk Summary & Technical Analysis for Trade Confirmation - khodrobank.com
Real time alert setup for 10x Genomics Inc. performanceJuly 2025 Update & Verified Momentum Stock Watchlist - Newser
What to do if you’re stuck in 10x Genomics Inc.2025 EndofYear Setup & Verified Trade Idea Suggestions - Newser
Is this a good reentry point in 10x Genomics IncJuly 2025 Decliners & Fast Entry Momentum Alerts - Newser
Technical signs of recovery in 10x Genomics Inc.Weekly Profit Report & Detailed Earnings Play Strategies - Newser
Should you hold or exit 10x Genomics Inc. nowTrade Analysis Summary & Detailed Earnings Play Alerts - Newser
Detecting support and resistance levels for 10x Genomics Inc.2025 Market Sentiment & Safe Entry Point Alerts - Newser
What are the future prospects of 10x Genomics Inc.July 2025 Final Week & Consistent Growth Equity Picks - khodrobank.com
What technical models suggest about 10x Genomics Inc.’s comebackIPO Watch & Low Drawdown Investment Strategies - Newser
How sentiment analysis helps forecast 10x Genomics Inc.Treasury Yields & Technical Pattern Based Buy Signals - Newser
10x Genomics Inc. Recovers — But Is It SustainableInsider Buying & Expert Approved Momentum Trade Ideas - beatles.ru
10x Genomics Inc. stock volume spike explainedWeekly Trade Recap & Intraday High Probability Alerts - Newser
Should you wait for a breakout in 10x Genomics IncPrice Action & Risk Managed Investment Signals - Newser
Is 10x Genomics Inc. stock poised for growthWeekly Profit Report & Reliable Volume Spike Trade Alerts - Newser
Published on: 2025-08-31 12:23:27 - Newser
What are 10x Genomics Inc.’s technical support levelsQuarterly Portfolio Review & Stock Market Timing Techniques - sundaytimes.kr
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
10 X Genomics Inc-Aktie (TXG) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Taich Adam | Chief Financial Officer |
Aug 22 '25 |
Sale |
13.79 |
22,315 |
307,657 |
309,273 |
Hindson Benjamin J. | See Remarks |
Aug 22 '25 |
Sale |
13.79 |
7,486 |
103,209 |
440,888 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):